Biogen (BIIB) News Today → The Worst is Yet to Come… (From Porter & Company) (Ad) Free BIIB Stock Alerts $224.94 +4.87 (+2.21%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 9:00 PM | globenewswire.comBIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the FirmJune 1 at 5:59 PM | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Short Interest Up 10.5% in MayBiogen Inc. (NASDAQ:BIIB - Get Free Report) was the target of a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 3,480,000 shares, a growth of 10.5% from the April 30th total of 3,150,000 shares. Based on an average daily volume of 1,220,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 2.4% of the company's shares are short sold.June 1 at 2:09 PM | marketbeat.comBank of Nova Scotia Purchases 130,169 Shares of Biogen Inc. (NASDAQ:BIIB)Bank of Nova Scotia lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 432.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 160,263 shares of the biotechnology company's stock aMay 31 at 6:03 PM | businesswire.comNASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc.May 31 at 5:35 PM | marketbeat.comEvoke Wealth LLC Invests $2.81 Million in Biogen Inc. (NASDAQ:BIIB)Evoke Wealth LLC bought a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,851 shares of the biotechnology company's stock, valued at approximaMay 31 at 11:14 AM | benzinga.comEurope Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative DisorderMay 30 at 9:02 PM | seekingalpha.comEU approves Biogen treatment for genetic form of ALSMay 30 at 7:02 PM | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) InvestorsMay 30 at 6:08 PM | reuters.comEuropean Commission grants marketing approval to Biogen's ALS drugMay 30 at 5:18 PM | marketbeat.comTreasurer of the State of North Carolina Buys 3,609 Shares of Biogen Inc. (NASDAQ:BIIB)Treasurer of the State of North Carolina grew its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 3.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 95,852 shares of the biotechnology company's stock after acquiring an additionaMay 30 at 5:00 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIBMay 30 at 4:51 PM | globenewswire.comBiogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALSMay 30 at 1:08 PM | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) InvestorsMay 30 at 12:07 PM | businesswire.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) InvestorsMay 30 at 4:18 AM | americanbankingnews.comBiogen's (BIIB) "Outperform" Rating Reaffirmed at Royal Bank of CanadaMay 30 at 4:00 AM | businesswire.comBIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 30 at 4:00 AM | prnewswire.comBIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 29, 2024 | sg.finance.yahoo.comBIIB Jun 2024 350.000 putMay 29, 2024 | marketbeat.comBiogen (NASDAQ:BIIB) Receives Outperform Rating from Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and issued a $317.00 price objective on shares of Biogen in a report on Wednesday.May 29, 2024 | sg.finance.yahoo.comBIIB Jan 2026 120.000 callMay 29, 2024 | sg.finance.yahoo.comBIIB Jun 2024 220.000 callMay 29, 2024 | markets.businessinsider.comShareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIBMay 29, 2024 | markets.businessinsider.comLost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyMay 28, 2024 | businesswire.comBiogen Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Against BIIBMay 28, 2024 | finance.yahoo.comIs Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals?May 27, 2024 | marketbeat.comEaton Financial Holdings Company LLC Purchases Shares of 5,062 Biogen Inc. (NASDAQ:BIIB)Eaton Financial Holdings Company LLC bought a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 5,062 shares of the biotechnology company's stock, valued at approximately $1,310,000. Other institutional invMay 27, 2024 | markets.businessinsider.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the FirmMay 27, 2024 | finance.yahoo.comThe Biggest Biotechnology Company in EuropeMay 26, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiogenMay 26, 2024 | finance.yahoo.comThe Biggest Publicly Traded Biotech CompanyMay 25, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Sells 180,219 Shares of Biogen Inc. (NASDAQ:BIIB)Robeco Institutional Asset Management B.V. trimmed its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 52.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 161,591 shares of the biotechnology company'May 25, 2024 | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Stock Holdings Raised by Primecap Management Co. CAPrimecap Management Co. CA raised its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 1.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,264,481 shares of the biotechnology compMay 24, 2024 | markets.businessinsider.comBiogen’s Strategic Diversification and Financial Strategy Garner Outperform RatingMay 24, 2024 | americanbankingnews.comBiogen (NASDAQ:BIIB) Earns "Buy" Rating from HC WainwrightMay 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Walgreens Boots Alliance (WBA)May 23, 2024 | prnewswire.comBIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 23, 2024 | businesswire.comKirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) InvestorsMay 23, 2024 | businesswire.comBIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 23, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the FirmMay 23, 2024 | stockhouse.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiogenMay 23, 2024 | markets.businessinsider.comBiogen’s Buy Rating Bolstered by Strategic Acquisition and Promising Pipeline ExpansionMay 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Biogen on Strategic Acquisition and Promising PipelineMay 23, 2024 | marketbeat.comFranklin Resources Inc. Trims Stock Holdings in Biogen Inc. (NASDAQ:BIIB)Franklin Resources Inc. trimmed its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 20.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 498,349 shares of the biotechnology company's stock afteMay 23, 2024 | marketbeat.comBiogen (NASDAQ:BIIB) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $300.00 price objective on shares of Biogen in a research report on Thursday.May 23, 2024 | businesswire.comBIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 23, 2024 | americanbankingnews.comBiogen (NASDAQ:BIIB) Rating Reiterated by Needham & Company LLCMay 22, 2024 | investopedia.comBiogen Buys Biotech Firm HI-Bio to Boost Its Immunology PortfolioMay 22, 2024 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIBMay 22, 2024 | bloomberg.comBiogen to Pay Up to $1.8 Billion for Immune Drug DeveloperMay 22, 2024 | finance.yahoo.comBiogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself. I call these Nvidia’s “Silent Partners.” BIIB Media Mentions By Week BIIB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIIB News Sentiment▼0.420.76▲Average Medical News Sentiment BIIB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIIB Articles This Week▼3217▲BIIB Articles Average Week Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Teva Pharmaceutical Industries News Today American Electric Power News Today Pinnacle West Capital News Today CRISPR Therapeutics News Today Portland General Electric News Today Denali Therapeutics News Today Vertex Pharmaceuticals News Today Regeneron Pharmaceuticals News Today Gilead Sciences News Today Alnylam Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIIB) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.